Metropolis Healthcare Limited has launched an advanced blood-based test aimed at enabling earlier detection and improved clinical decision-making in Alzheimer’s disease.

Metropolis’ newly launched test enables minimally invasive screening through a simple blood sample, allowing clinicians to assess the likelihood of Alzheimer’s-related changes and guide next steps in care. The approach aligns with 2025 clinical practice recommendations from the Alzheimer’s Association, which endorse blood-based biomarkers such as pTau217 and the β-amyloid 1–42 ratio for individuals with cognitive impairment.

Backed by clinical evidence demonstrating over 90% diagnostic accuracy and strong concordance with amyloid PET imaging, the test offers a reliable and more convenient alternative to traditional methods like PET scans and cerebrospinal fluid (CSF) testing. It can serve as an initial screening tool, helping physicians determine whether advanced diagnostic procedures are required.

Surendran Chemmenkotil, Managing Director, Metropolis Healthcare Limited, said: “As India’s population ages, timely and accessible diagnostics for neurodegenerative diseases are becoming increasingly important. At Metropolis, we are expanding access to advanced testing that enables earlier evaluation and better clinical decisions. This test serves as a critical first step in the diagnostic pathway, helping identify patients who need further evaluation while reducing unnecessary procedures. It reflects our commitment to a more proactive and integrated approach to neurological care.”

Dr. Kirti Chadha, Chief Scientific and Innovation Officer, Metropolis Healthcare Limited, said: “In Alzheimer’s care, blood-based biomarkers can provide an additional layer of objective evidence for early-stage clinical decision making. It is important to note that not all blood-based assays meet the rigorous standards set forth, hence ensuring optimum quality standards and test validation protocols is of utmost importance. The results should always be interpreted in the context of a comprehensive clinical evaluation.”